Outlook Therapeutics (OTLK) Common Equity (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Common Equity of -$29.0 million for Q1 2026, up 10.68% year-over-year from -$26.2 million in Q1 2025, and up 24.79% quarter-over-quarter from -$38.5 million in Q4 2025.
Outlook Therapeutics (OTLK) Common Equity (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Common Equity for 12 consecutive years, with -$29.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 10.68% year-over-year to -$29.0 million; the TTM figure through Mar 2026 stood at -$29.0 million (up 10.68% YoY), while the FY2025 annual figure was -$32.2 million, up 55.95% from the prior year.
- Common Equity advanced to -$29.0 million in Q1 2026 per OTLK's latest filing, from -$38.5 million in the prior quarter.
- Across five years, Common Equity topped out at $36.0 million in Q1 2022 and bottomed at -$134.2 million in Q1 2024.
- Historically, Common Equity has averaged -$27.3 million across 5 years, with a median of -$29.0 million in 2026.
- Annual changes were most pronounced in 2022 — Common Equity surged 89.62% — and 2024, when it sank 1420.55%.
- Outlook Therapeutics' Common Equity stood at $15.8 million in 2022, then plunged by 254.48% to -$24.3 million in 2023, then tumbled by 106.59% to -$50.3 million in 2024, then rose by 23.35% to -$38.5 million in 2025, then advanced by 24.79% to -$29.0 million in 2026.
- Business Quant data shows OTLK's Common Equity at -$29.0 million in Q1 2026, -$38.5 million in Q4 2025, and -$32.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | -10.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.99 Mn |
| Dec 31, 2025 | -38.55 Mn |
| Sep 30, 2025 | -32.19 Mn |
| Jun 30, 2025 | -37.19 Mn |
| Mar 31, 2025 | -32.46 Mn |
| Dec 31, 2024 | -50.29 Mn |
| Sep 30, 2024 | -73.08 Mn |
| Jun 30, 2024 | -83.67 Mn |
| Mar 31, 2024 | -134.24 Mn |
| Dec 31, 2023 | -24.34 Mn |
| Sep 30, 2023 | -14.44 Mn |
| Jun 30, 2023 | -5.50 Mn |
| Mar 31, 2023 | 10.49 Mn |
| Dec 31, 2022 | 15.76 Mn |
| Sep 30, 2022 | 8.74 Mn |
| Jun 30, 2022 | 20.08 Mn |
| Mar 31, 2022 | 35.96 Mn |
| Dec 31, 2021 | 48.82 Mn |
| Sep 30, 2021 | 4.61 Mn |
| Jun 30, 2021 | 12.75 Mn |